DISTRIBUTED BY

ariste health

RECHARGE-FREE SCS SYSTEM

PROCLAIM™ XR

BE BOLD.
EMPOWER YOUR PATIENTS TO
LIVE XR.

Abbott

INTRODUCING THE PROCLAIM™ XR SCS SYSTEM.

The latest patient-centric innovation exclusively from Abbott.

PROCLAIM™ XR SCS SYSTEM BENEFITS INCLUDE:

- Up to 10-year battery life at low dose settings*
- Freedom from the hassles of recharging
- Superior** BurstDR™ stimulation therapy[3]
- Familiar Apple‡ devices
- Upgradeable platform
- Full-body MR Conditional labeling***

MAKE THE BOLD CHOICE.

Give your patients superior** pain relief with the Proclaim XR SCS System and a battery that lasts up to 10 years at low dose settings* without the hassles of recharging.

FOR MORE INFORMATION.
VISIT PROCLAIMXR.COM/INT.

LOWER THE DOSE. **RAISE YOUR EXPECTATIONS.**

By delivering low doses of stimulation, the system's battery can last up to 10 years* without the burden of recharging.



BE CONFIDENT IN THE THERAPEUTIC WINDOW.

Dosing stimulation can maintain therapeutic effect while lowering risk of overstimulation.[1]

A PROPRIETARY WAVEFORM
THAT IS UNIQUELY DOSABLE.

BurstDR™ stimulation is a unique and proprietary waveform that mimics natural firing patterns in the brain.[22]





1. NON-LINEAR CHARGE ACCUMULATION

Its unique waveform produces a non-linear charge accumulation.

2. OBSERVED CARRY-OVER EFFECT

Which leads to an observed carry-over effect,[2] meaning therapy is effective even after stimulation is turned off.[1]

3. SUPERIOR** RELIEF FROM PAIN AND SUFFERING†[3]

Producing a therapy powerful enough to provide consistent, repeatable[1, 3-20] and superior** relief from pain and suffering.†[3]

4. IMPROVES PHYSICAL, MENTAL AND SOCIAL HEALTH FUNCTIONS

Providing the patient better quality of life.[23]

BOLDXR™ DOSING PROTOCOL.

The Proclaim™ XR SCS System harnesses the power of low-energy BurstDR stimulation, coupled with the BoldXR™ Dosing Protocol, to extend battery life and provide pain relief without the hassle of recharging.[1]

BASED ON THE BOLD STUDY, AT 6 MONTHS[1]:

100% of patients remained on dosed settings using 6 hours or less of stimulation per day.

Nearly 50% of patients remained on the lowest dose setting using only 1.8 hours of stimulation per day.

DOSED BURSTDR™ STIMULATION

- **Delivered statistically significant reduction in pain.[1]**
- **Led to improved quality of life.[1]**

THE BOLDXR DOSING PROTOCOL.

- Provides simple and effective programming that identifies the lowest therapeutic dose.[1]
- Is based on the BOLD clinical study, which demonstrated that dosing BurstDR stimulation results in patients receiving minimal stimulation while maintaining therapeutic effect.[1]
- May uniquely address therapy longevity by reducing stimulation on-time.[1,21]

The BoldXR™ Dosing Protocol is only a guide and each patient should be programmed as needed to ensure the best outcome. It should not replace the Instructions for Use (IFU) or recommendations and advisement of the treating healthcare practitioner.

BurstDR™ stimulation, patented technology exclusively from Abbott, is also referred to as Burst stimulation in clinical literature.

*Up to 10 years of battery longevity at the lowest dose setting: 0.6mA, 500 Ohms, duty cycle 30s on/360s off. NOTE: In neurostimulation therapy, 'dose' refers to the delivery of a quantity of energy to tissue. Safety comparisons and specific dose-response curves for each dosage have not been clinically established. Refer to the IFU for additional information. Hassle-free means recharge-free.

**When compared to traditional tonic stimulation.

***Within approved parameters. Refer to the IFU for full details on the MR Conditional scan parameters.

†Pain and suffering as measured by VAS.

1. Deer T. Efficacy of Burst Spinal Cord Stimulation Microdosing in a De-Novo Patient. Poster presented at NAPA Pain 2019.
2. Saber M, Schwabe D, et al. Rat fMRI brain responses to noxious stimulation during tonic, burst, and burst-microdosing spinal cord stimulation. NANS summer series; 2018; New York, NY.
3. Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. *Neuromodulation*. 2017;20(6):543-552.
4. De Ridder D, Vanneste S, Plazier M, van der Loo E, Menovsky T. Burst spinal cord stimulation: toward paresthesia-free pain suppression. *Neurosurgery*. 2010;66(5):986-990.
5. Bara B, Schu S, Vesper J. First results of Burst high frequency stimulation in failed FBSS stimulation patients. One year follow up. *Neuromodulation*. 2013;16(5):e136.
6. De Ridder D, Plazier M, Kamerling N, Menovsky T, Vanneste S. Burst spinal cord stimulation for limb and back pain. *World Neurosurgery*. 2013;80(5):642-649.e641.
7. Schu S, Slotty PJ, Bara G, von Knop M, Edgar D, Vesper J. A prospective, randomised, double-blind, placebo-controlled study to examine the effectiveness of burst spinal cord stimulation patterns for the treatment of failed back surgery syndrome. *Neuromodulation*. 2014;17(5):443-450.
8. Espinet A, Courtney P, Mitchell B, et al. Burst spinal cord stimulation provides superior overall pain relief compared to tonic stimulation. *Pain Practice: The Official Journal of World Institute of Pain*. 2014;14(s1):114.
9. de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D. Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. *Neuromodulation*. 2014;17(2):152-159.
10. Courtney P, Espinet A, Mitchell B, et al. Improved Pain Relief With Burst Spinal Cord Stimulation for Two Weeks in Patients Using Tonic Stimulation: Results From a Small Clinical Study. *Neuromodulation*. 2015;18(5):361-366.
11. De Ridder D, Lenders MW, De Vos CC, et al. A 2-center comparative study on tonic versus burst spinal cord stimulation: amount of responders and amount of pain suppression. *Clinical Journal of Pain*. 2015;31(5):433-437.
12. Tjepkema-Cloostermans MC, de Vos CC, Wolters R, Dijkstra-Scholten C, Lenders MW. Effect of Burst Stimulation Evaluated in Patients Familiar With Spinal Cord Stimulation. *Neuromodulation*. 2016;19(5):492-497.
13. Colini-Baldeschi G, De Carolis G, Papa A, et al. Burst stimulation for chronic low back and leg pain. 8th World Congress of the World Institute of Pain; 2016; New York, USA.
14. Kretzschmar M, Vesper J, Van Havenbergh T, et al. Improved pain and psychosocial function with Burst SCS: 1 year outcomes of a prospective study. *Neuromodulation*. 2017;20(7):e450.
15. Kinfe TM, Muhammad S, Link C, Roeske S, Chaudhry SR, Yearwood TL. Burst Spinal Cord Stimulation Increases Peripheral Antineuroinflammatory Interleukin 10 Levels in Failed Back Surgery Syndrome Patients With Predominant Back Pain. *Neuromodulation: Technology at the Neural Interface*. 2017;20(4):322-330.
16. Wahlstedt A, Leljevahl E, Venkatesan L, Agnesi F. Cervical burst spinal cord stimulation for upper limb chronic pain: A retrospective case series. Poster presented at 16th Annual Pain Medicine Meeting; 2017; Lake Buena Vista, FL.
17. Muhammad S, Roeske S, Chaudhry SR, Kinfe TM. Burst or High-Frequency (10 kHz) Spinal Cord Stimulation in Failed Back Surgery Syndrome Patients With Predominant Back Pain: One Year Comparative Data. *Neuromodulation*. 2017;20(7):661-667.
18. Deer T, et. al. Randomized, Controlled Trial Assessing Burst Stimulation for Chronic Pain: Two-year Outcomes from the SUNBURST Study. Poster presented at North American Neuromodulation Society Meeting; 2018; Las Vegas, NV.
19. St. Jude Medical™ Proclaim™ Neurostimulation System Clinician's Manual. Plano, TX. 2018.
20. Kriek N, et al. Preferred frequencies and waveforms for spinal cord stimulation in patients with complex regional pain syndrome: a multicenter, double-blind, randomized and placebo-controlled crossover trial. *European Journal of Pain*. 2017;21(3):507-519.
21. Byrne JH. Analysis of synaptic depression contributing to habituation of gill-withdrawal reflex in Aplysia californica. *Journal of Neurophysiology*. 1982;48(2):431-438.
22. De Ridder D, Vanneste S, Plazier M, Vancamp T. Mimicking the brain: Evaluation of St. Jude Medical's Prodigy Chronic Pain System with Burst Technology. *Expert Review of Medical Devices*. 2015;12(2):143-150.
23. Chakravarthy K, Malayil R, Kirketeig T, Deer T. Burst Spinal Cord Stimulation: A Systematic Review and Pooled Analysis of Real-World Evidence and Outcomes Data. *Pain Medicine*. 2019;20:S47-S57.

Abbott
One St. Jude Medical Dr., St. Paul, MN 55117 USA
Tel: 1 651 756 2000
Neuromodulation.Abbott

Brief Summary: Prior to using Abbott devices, please review the Clinician's Manual for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system. **Indications for Use:** Spinal cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain. **Contraindications:** Patients who are unable to operate the system or who have failed to receive effective pain relief during trial stimulation. **Warnings/Precautions:** Diathermy therapy, implanted cardiac systems or other active implanted devices, magnetic resonance imaging (MRI), electrosurgery, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage. Patients who are poor surgical risks, with multiple illnesses, or with active general infections should not be implanted. **Adverse Effects**: Unpleasant sensations, undesirable changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain at the electrode or IPG site, seroma at IPG site, allergic or rejection response, battery failure. Clinician's Manual must be reviewed for detailed disclosure.

49105 MAT-1900659 v3.0 | Item approved for audiences in EMEA.

Ariste Health. C8 Northlands Deco Park, 2 New Market Road, Northriding, 2169, Johannesburg, South Africa
Tel: +27 11 463 4723 • Email: info@aristehealth.com
www.aristehealth.com